Clinical trial tested how CBD changes THC effects when taken together orally
A randomized clinical trial in healthy adults found that co-administered CBD altered THC pharmacokinetics and pharmacodynamics in a dose-dependent manner, providing controlled data on how the two cannabinoids interact when taken orally.
Quick Facts
What This Study Found
CBD co-administration modified THC blood levels and subjective effects in a dose-dependent pattern. The pharmacokinetic and pharmacodynamic interactions between oral THC and CBD varied depending on the ratio of the two cannabinoids.
Key Numbers
Multiple oral cannabis extract formulations with varying THC:CBD ratios tested. Blood THC levels and subjective effects measured. Dose-dependent CBD modulation of THC observed.
How They Did This
Randomized clinical trial in healthy adults. Compared pharmacokinetics and pharmacodynamics of orally administered cannabis extracts varying in THC and CBD concentrations. Measured blood levels and subjective effects.
Why This Research Matters
CBD is widely believed to counteract THC effects, but controlled clinical data has been limited. This trial provides rigorous pharmacological evidence on how the two most prominent cannabinoids interact in humans.
The Bigger Picture
The THC-CBD interaction is central to cannabis product design and medical cannabis prescribing. Rigorous pharmacokinetic data helps move from anecdotal "entourage effect" claims to evidence-based formulation decisions.
What This Study Doesn't Tell Us
Healthy adult volunteers may not reflect patients with medical conditions. Oral administration only (inhaled routes may produce different interactions). Acute dosing study does not capture chronic use dynamics. Specific extract formulations may not represent all commercial products.
Questions This Raises
- ?Does the THC-CBD interaction differ with chronic use?
- ?Would different delivery routes (inhaled, sublingual) show the same pharmacokinetic patterns?
Trust & Context
- Key Stat:
- CBD dose-dependently modified THC pharmacokinetics and pharmacodynamics
- Evidence Grade:
- Randomized clinical trial with pharmacokinetic and pharmacodynamic endpoints. Rigorous design for a drug interaction study.
- Study Age:
- Published 2023.
- Original Title:
- Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
- Published In:
- JAMA network open, 6(2), e2254752 (2023)
- Authors:
- Zamarripa, C Austin(9), Spindle, Tory R(18), Surujunarain, Renuka, Weerts, Elise M, Bansal, Sumit, Unadkat, Jashvant D, Paine, Mary F, Vandrey, Ryan
- Database ID:
- RTHC-05050
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Does CBD reduce the effects of THC?
This clinical trial found the interaction is more nuanced than a simple reduction. CBD altered THC blood levels and subjective effects in a dose-dependent manner, meaning the ratio between the two matters. Some effects were attenuated while the pharmacokinetic picture was complex.
Why does the THC:CBD ratio matter?
Different ratios of THC to CBD produced different blood level profiles and subjective effects in this trial. This means that cannabis products with the same total cannabinoid content but different ratios could produce meaningfully different experiences and therapeutic effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05050APA
Zamarripa, C Austin; Spindle, Tory R; Surujunarain, Renuka; Weerts, Elise M; Bansal, Sumit; Unadkat, Jashvant D; Paine, Mary F; Vandrey, Ryan. (2023). Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.. JAMA network open, 6(2), e2254752. https://doi.org/10.1001/jamanetworkopen.2022.54752
MLA
Zamarripa, C Austin, et al. "Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.." JAMA network open, 2023. https://doi.org/10.1001/jamanetworkopen.2022.54752
RethinkTHC
RethinkTHC Research Database. "Assessment of Orally Administered Δ9-Tetrahydrocannabinol Wh..." RTHC-05050. Retrieved from https://rethinkthc.com/research/zamarripa-2023-assessment-of-orally-administered
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.